ALC - Good News For Dry Eye Disease Patients: Eye Care Focused Alcon's Treatment Shows Encouraging Benefit In Late-Stage Trials | Benzinga
Alcon (NYSE: ALC) released topline results from the two Phase 3 trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED).
In both COMET-2 and COMET-3, which enrolled more than 930 dry eye subjects in total (randomized 1:1 to AR-15512 or vehicle control), the primary endpoint of the proportion of subjects with at least a 10-mm ...